Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celltran clinches £1m funding:

This article was originally published in Clinica

Executive Summary

UK wound care therapy developer Celltran is accelerating the development and commercialisation of its core products after securing £1m ($2m) in additional funding. The Sheffield-based company said its Ulcodress plus (for treating static chronic wounds) and Cryoskin (for treating burns) products are poised to enter the market. It already has a revenue-generating product, Myskin, available in the UK, while Lyphoderm, a wound care product made from freeze-dried donor skin cells, is about to enter phase III trials. The financing round was led by Yorkshire Fund Managers and included contributions from all Celltran's existing shareholders including South Yorkshire Investment Fund, Innogetics, Biofusion, White Rose Technology Seedcore Fund and PUK Ventures.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049619

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel